Quidel

News Release

Printer Friendly Version View printer-friendly version
<< Back
Quidel Corporation to Present at CCBN Virtual Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Dec. 6, 2002--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced that it will be presenting at the CCBN Virtual Healthcare Conference on Tuesday, December 10, 2002, at 2:15 p.m. Eastern (11:15 a.m. Pacific).

S. Wayne Kay, Quidel's president and chief executive officer, will present during the live webcast and take questions from participants. Interested investors can access the presentation from the investor relations section of the company Web site at www.quidel.com.

The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investor can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the webcast via CCBN's password protected event management site, StreetEvents, at www.streetevents.com.

Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost- effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at http://www.quidel.com.

CONTACT:
Quidel Corporation
Paul E. Landers, 858/552-7962
www.quidel.com
or
Investor Contacts:
Lippert/Heilshorn & Associates, Inc.
Bruce Voss, 310/691-7100
bvoss@lhai.com
Ina McGuinness, 310/691-7100
imcguinness@lhai.com
www.lhai.com